Fig. 1From: Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetesMeta-analysis evaluating the efficacy of SGLT-2i (empagliflozin, canagliflozin and dapagliflozin) on MACE according to basal eGFR values in four trials (EMPA-REG, CANVAS, DECLARE and CREDENCE)Back to article page